become a member

Loading...

Introduction to Product Liability Regarding
FDA-Regulated Products

Recorded July 23, 2019 | On-Demand Webinar

Buy Now

This webinar will provide an overview of product liability law as related to FDA-regulated products. We will discuss types of product liability claims, class actions and multi-district litigation, individual lawsuits, and consolidated trials. We will also cover typical types of cases and theories, the interplay between FDA regulation and litigation, and steps companies can take to protect against product liability lawsuits.

Get Access

$99

+$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

Speakers

Kathleen Hardway, Partner, Venable LLP
Chris McRae, Partner, Shook, Hardy & Bacon LLP
Richard Underwood, Managing Engineer, Exponent, Inc.
Kirke Weaver, Vice President, Office of General Counsel, Merck

Virtual Learning FAQ

When will I receive my session?

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

Is my computer/mobile device compatible?

On-demand content can be played back on most devices.

Is CLE credit available?

CLE credit is not currently available for pre-recorded sessions.

Related Content

Social Media Spotlight: FDA Compliance for TikTok, X, LinkedIn, and Other Content

Cosmetic Safety and Contaminants: PFAS, State Versus Federal Regulation, and More

The Regulation of Biological Product Marketing: An Introduction

Post-Approval Pharmacovigilance of Biological Products: An Introduction

Biologics and Biosimilars: An Introduction

Biological Product Approval, Vaccines, Emergency Use Authorization: An Introduction

Introduction to Human Cellular and Tissue Based Products (HCT/P), Cell Therapy and Gene Therapy

Regulation of Biological Product/Drug Development: An Introduction

Introduction to FDA Review and Approval of Biological Products

Overview of Biological Products Law and FDA’s Regulatory Processes

An Introduction to Drug Enforcement: FDA Enforcement Authorities, Tools, Violations and Initiatives

Regulation of Drug Marketing: An Introduction

Regulation of Drug Manufacturing: An Introduction

Regulation of Over-the-Counter (OTC) Drugs: An Introduction

The Regulation of Biologics and Biosimilars: An Introduction

Post Approval Requirements for Drugs: An Introduction to Safety Reporting and Post-Approval Changes

An Introduction to the Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues

The New Drug Approval Process: NDA Submission and Review

The New Drug Approval Process: New Drug Research and Development

The New Drug Approval Process: Basic Concepts

Origins and Overview of Drug Law Regulation: An Introduction

USPTO-FDA Collaboration: Progress Towards Patently True Interagency Coordination

International Issues for Medical Device Manufacturers: An Introduction

An Introduction to the Regulation of Promotion and Advertising for Medical Devices

FDA Authorities and Processes for the Enforcement, Compliance, and Inspection of Medical Devices

Regulatory Requirements for Medical Device Manufacturing and Quality System (QS) Regulation: An Introduction

Post Marketing Issues for Medical Devices: An Introduction

An Introduction to Coverage, Coding, and Payment of Medical Devices – Collaboration Between FDA and the Centers for Medicare and Medicaid Services (CMS)

Medical Device Premarket Approval Applications (PMA); Humanitarian Device Exemption (HDE) and Breakthrough Devices: An Introduction

An Introduction to the Medical Device Approval Process: Premarket Notification 510(k) and De Novo Requests

Medical Device Clinical Investigations: An Introduction

Regulation of Digital Health Products: An Introduction

An Introduction to the Regulation of Combination Products for Medical Devices

Overview of Medical Device Law and Regulation

Enhancing Engagement Opportunities and Communication with FDA

Collaboration Across Agencies: Understanding the Role of FDA, USDA, and EPA in Food Regulation

Current Trends in FCPA and FCA Enforcement: Identifying Fraudulent Practices and Mitigating Risk

Recent Rulings on Mifepristone Access: Implications for FDA and Stakeholders

Meet MoCRA: Getting to Know the Modernization of Cosmetics Regulation Act

Psychedelics Meet Mainstream Medicine: Overcoming Regulatory Uncertainty and Addressing Patient Safety Challenges

The Drug Supply Chain Security Act: Implementation Challenges, Industry Compliance, and Best Practices

Advocacy Without Antagonism: Principled Counseling in Food and Dietary Supplement Class Actions

Implementation of the Inflation Reduction Act: Healthcare Reform and Implications for the Pharmaceutical Industry

The Future of Food Regulation: Assessing the Reagan-Udall Foundation’s Report on FDA’s Human Foods Program

Fundamentals of FDA Regulation of Cosmetics

FDLI Book Launch—How FDA Really Works: Insights from the Experts

Supply Chain Mayhem: Industry Impacts and What Can be Done

Updates and Developments in Drug Compounding

Essentials of Post-Inspection Actions: From FDA Notices to Criminal Prosecution

Essentials of Inspection Readiness for Medical Products

Essentials of FDA, DOJ, FTC Enforcement Authorities

You Can’t Outsource Responsibility: Managing Quality in a Contract Manufacturing Partnership

Over-the-Counter Drugs Monograph Reform – How’s it Going?

FDA’s COVID-19 Activities

FDA’s Expedited Programs: Understanding Which Program Best Suits Your Product

Food Law in China: Overview, Practical Considerations, and Recent Developments

The Promise and Problem of Blockchain for Medical Products: What Lawyers Need to Know

Navigating the Complexities of Combination Product Regulation

Medical Device Clinical Investigations: An Introduction to Sponsor Responsibilities and Compliance Issues

Medical Device Manufacturer Requirements: An Introduction to Registration and Listing of Establishments

FDA and Centers for Medicare and Medicaid Services: Regulatory Considerations for Communicating and Contracting for Value

Best Practices for Drug Recalls

Machine Learning for Regulatory Attorneys and English Majors

The Essentials of Statistics for Medical Products Lawyers

The Essentials of Clinical Trial Science

How Does FDA’s Recent Guidance on Remote Interactive Evaluations Change the Inspections Landscape?

Biologic and Biosimilar Litigation and IP Rights

The Impact of COVID-19 on the In Vitro Diagnostic Industry

Prop 65 Trends and Issues: Food and Dietary Supplements

Introduction to Vaccine Regulation

Vaccine Development and Clinical Trials

Vaccine Pathways to Market

Vaccine Manufacturing, Scaling, Supply Chain, and Administration Issues

Vaccine Enforcement and Litigation

Examining the State of Drug Importation and Drug Pricing

FDA’s Legal Authority Over Laboratory Developed Tests

Compounding Drug Products Due to Supply Chain Access in Light of COVID-19

FDA’s Compounding Memorandum of Understanding with States: Questions, Concerns, and What’s Next

Continued Reliance on Foreign Drug Manufacturing and the Drug Supply Chain: Manageable Risk or Public Health Concern?

State of FDA Medical Product Manufacturer Inspections During and After COVID-19

Restarting Clinical Trials in the Wake of COVID-19

Animal Drug Compounding: FDA’s New Guidance and Impacts on Industry

COVID-19 and Beyond: Development and Implementation of Recovery Action Plans for Medical Product Manufacturers

The Long-Awaited Biologics Transition Date Has Come: What Now?

FDA’s Recent COVID-19 Guidances Facilitating Expanded Access to Certain Medical Products

What are FDA’s Tools for Responding to Public Health Emergencies Such as the Coronavirus (COVID-19)?

FDA-Related Congressional Committees: Jurisdiction, Focus, and Roles

The CREATES Act Has Passed: What Does It Mean for the Generics Industry?

Reducing Anti-Kickback Risks Associated with Medical Products

Class Action of FDA-Regulated Products: Recent Updates and Future Forecasts

Introduction to Product Liability Regarding FDA-Regulated Products

Due Diligence: Ensuring Your Deal Doesn’t Collapse Due to Regulatory, Clinical, Quality, or Data Integrity Issues

Single, Shared System Risk Evaluation and Mitigation Strategies: Opportunities and Challenges

New Management Standards for Hazardous Waste Pharmaceuticals and Nicotine

Patient Assistance Programs: Recent Enforcement and Best Practices

FDA in Partial Shutdown – What Do We Know About Who’s Doing What?

Opioid Legislation: The Path Forward for FDA and DEA Webinar

From Approval to Coverage – FDA and CMS Jurisdictional Lines

Guidance on Guidance: FDA, DOJ, and Enforcement

Drug Pricing for the Food and Drug Community

Organic Chemistry for the Food and Drug Community

DEA Law for the Food and Drug Community

Data Integrity: FDA Enforcement and Risk-Reduction Considerations

First Amendment Issues in Advertising and Product Packaging Webinar

New Medical Device Requirements and Where Manufacturers Should Focus: MDUFA, FDARA, and 21st Century Cures

Real World Evidence: Data Requirements, Utilization, and Presentation

Editorial or Ad? FTC’s Native Advertising Guidelines and Challenges for Industry

Development of Medical Devices: Best Practices for Safeguarding Your IP and FDA Rights

PDUFA and BsUFA Reauthorization: Key Changes Affecting Industry and Patients

The EU’s New Medical Device and IVD Regulations

REMS: Key Issues and Best Practices

Compounding Still in the Mix: Title I of the DQSA, the Compounding Quality Act, Three Years Later

False Claims Act Enforcement

Recent FDA Guidance Documents on Manufacturer Communications about Medical Products

21st Century Cures Act

The Yates Memo: A Lawyer’s Professional Responsibility

Social Media: Innovative Uses and Practical Experiences

Open Payments Data and the Sunshine Act: Managing the Risk of Transparency

admin2020-05-19T13:04:13-04:00